Anti-HER2/Neu passive-aggressive immunotherapy

Eric D. Mortenson, Yang Xin Fu

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Preclinical studies have established that CD8+ T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ER BB2, best known as HER 2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER 2/Neu therapy also requires CD4+ T cells and CD40/ CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.

Original languageEnglish (US)
Article numbere27296
Issue number1
StatePublished - 2014


  • Adaptive immunity
  • Antibody
  • CD4
  • CD40
  • CD40L
  • CD8
  • HER2
  • Herceptin
  • Immunotherapy
  • Neu

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Anti-HER2/Neu passive-aggressive immunotherapy'. Together they form a unique fingerprint.

Cite this